Vaxinia MAST Trial:
47 heavily pre-treated patients have been dosed to date (24 April 2024), of which 40 patients are evaluable meaning they received at least their first scan at day 42
• Nearly half of the evaluable patients (48%) have remained on treatment for more than 3 months, representing significant disease control; 3 monotherapy patients have remained on treatment for over 200 days
perhaps a new update soon ?
onCARlytics OASIS Trial:
Preliminary early combination data are expected in the fourth quarter of 2024.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
-0.002(10.0%) |
Mkt cap ! $100.8M | |||
| Open | High | Low | Value | Volume |
| 1.5¢ | 1.5¢ | 1.3¢ | $232.4K | 16.58M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 66 | 21047608 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 4957928 | 17 |
View Market Depth
| Last trade - 15.38pm 17/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |